5 conditions, such as hypertension and vascular injury (Otsuka et al., 1998; Touyz et al., 1999; Hutchinson et al., 1999) . These evidence suggest that the upregulation of vascular AT 2 receptors under pathological conditions is one of the compensatory mechanisms of vessels counteracting the AT 1 -mediated contractile response to Ang II to protect vessels from the mechanical overload. To test this hypothesis, we used a rat model of pressure-induced left ventricular hypertrophy (Doggrell and Brown, 1998) produced by suprarenal abdominal aortic coarctation (banding) to determine how the increased transmural pressure influences the vascular AT 2 receptor expression and thereby changes the contractile response to Ang II.
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JPET Fast Forward. Published on November 10, 2003 as DOI: 10.1124 at ASPET Journals on July 9, 2017 jpet.aspetjournals.org Downloaded from 7 sham procedure for control rats included injection of the same amount of anesthetic, in incision of approximately the same size, and the placement of a loosely tied ligature at the exact same position on the abdominal aorta.
Losartan was dissolved in saline and administered i.p. at a dose of 1 mg/kg once a day for 7 days. Candesartan was suspended in 10% gum Arabic and administered orally at a dose of 2 mg/kg once a day for 7 days.
Blood pressure measurement
The patency of the aortic banding was assessed by measuring the blood pressure of carotid artery under pentobarbital anesthesia (pentobarbital sodium 50 mg/kg, i.p.). To measure the blood pressure, the left carotid artery was cannulated with a PE-10 polyethylene catheter, and pulse wave forms were monitored by a polygraph system (Nihon Kohden, Tokyo, Japan).
Assays of plasma renin concentration (PRC) and activity (PRA)
Blood was collected from the abdominal aorta into a syringe containing 1/10 volume of 3.8% sodium citrate under ether anesthesia. Following centrifugation at 800 g for 15 min, plasma samples were collected and stored at -90˚C until assays. PRC or PRA in plasma samples were determined by radioimnmunoassay of Ang I liberated in the presence or absence of plasma from bilaterally nephrectomized rats, respectively, as described previously (Ohtani et al., 1989) . This article has not been copyedited and formatted. The final version may differ from this version.
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Analysis of AT 1 and AT 2 receptor mRNAs by reverse transcription-polymerase chain reaction (RT-PCR)
Animals were sacrificed under ether anesthesia 4, 7, 14, and 28 days after aortic banding or sham-operation. Age-matched untreated rats were also sacrificed as a control. The excised thoracic aorta (approximately 10 mg) was stripped of adventitia, then homogenized in acid guanidinium-phenol-chloroform to extract total RNA, as described previously (Yayama et al., 2003) . To detect AT 1 and AT 2 receptor mRNAs, we used two methods: one was RT-PCR followed by Southern blotting with respective specific probes, and second was quantitative real-time RT-PCR. Reverse transcription was performed in a reaction volume of 4 µL containing 0.3 µg RNA, 1.55 µL of dNTP (10 mmol/L), 0.8 µL of MgCl 2 (20 mmol/L), 0.4 µL of 10 x buffer (500 mmol/L KCl in 0.1 mol/L Tris-HCl, pH 8.3,), 0.05 µL of 10 unit enzyme (Moloney murine leukemia virus reverse transcriptase), and 0.2 µL of reverse-primer (50 pmol/µL). The mixture was incubated at 42˚C for 15 min, 95˚C for 5 min, then 4˚C for 5 min to allow synthesis of the first strand cDNA. The cDNA was amplified in a 20-µL reaction mixture containing 10 pmol of the forward primer, 1.6 µL of 10 x buffer, 4 µL of MgCl 2 (25 mmol/L), and 0.5 units of Taq DNA polymerase at 95˚C for 9 min, at 94˚C for 1 min, and annealing at 54˚C (AT 1 receptor), 56˚C (AT 2 receptor) or 60˚C (glyceraldehyde phosphate dehydrogenase; GAPDH) for 2 min, then extension at 72˚C for 3 min followed by at 72˚C for 10 min. The amplification cycles were 35 for the AT 1 receptor, 40 for the AT 2 receptor and 25 for GAPDH. After amplification, the PCR products were electrophoresed on a 1.5% agarose gel, then denatured, neutralized and transferred 9 onto a nylon membrane by capillary blotting and cross-linked by UV irradiation. The For quantitative measurement of the AT 2 receptor mRNA, 0.3 µg RNA samples from the thoracic aorta were reverse-transcribed using a reverse primer (5'-ATACCCATCCAGGTCAGAGCAT-3') as described above. The cDNA products in 2 µL were mixed with 18 µL of TaqMan Master Mixture (2 µL of 10 x buffer, 2.8 µL of MgCl 2 (20 mmol/L), 2 µL of reverse primer (3 µmol/L), 2 µL of forward primer (3 µmol/L), 2 µL of TaqMan probe (2 µmol/L), 0.4 µL of 10 mM dUTP, 0.1 µL of uracil N-glycosylase (1 unit/µl) and 0.1 µL of Taq DNA polymerase (5 unit/µl)). PCR was carried out in an ABI Prism 7700 system (Applied Biosystems, Tokyo, Japan) under the following conditions: 50˚C for 2 min. 95˚C for 10 min, 40 cycles at 95˚C for 15 sec, and 60˚C for 1 min. The PCR results were analyzed with the Sequence Detector 1.6
program (Perkin-Elmer, Norwalk, USA). For the AT 2 -receptor, the following primers and probes were used: forward primer, 5'-CCCGTGACCAAGTCTTGAAGAT-3'; reverse primer, 5'-ATACCCATCCAGGTCAGAGCAT-3'; TaqMan probe, This article has not been copyedited and formatted. The final version may differ from this version. 1.2, NaHCO 3 25, glucose 11.1. The aortas were cleaned of adherent connective tissue and cut into rings (3 mm long). Each ring was fixed vertically under a resting tension of 1.0 g in a 10-mL organ bath filled with the solution (37°C, pH 7.4) described above.
In some rings, the endothelium was mechanically removed by gentle rubbing with moistened cotton. The bath solution was continuously aerated with a gas mixture of 95% O 2 /5% CO 2 , and then the rings were allowed to equilibrate for 90 min before the start of the experiments. Isometric tension change was measured with a force-displacement transducer (model t-7; NEC San-Ei, Tokyo, Japan) coupled to a dual-channel chart recorder (model 8K21; NEC San-Ei). After reaching equilibrium, cumulative concentration-response curves were constructed for Ang II (10 -10 -10 
Assay of cyclic GMP (cGMP) in aortic rings
Aortic rings were fixed in a 10-mL organ bath filled with Krebs-Henseleit solution as described above. After allowing equilibration for 1 h, IBMX (5 x 10 -5 M) was added to the organ bath. Twenty-five minutes after the addition of IBMX, the rings were stimulated with Ang II (1 x 10 -7 M) for 5 min. In some experiments, L-NAME (1 x 10 -4 M) was added at the same time as the IBMX addition. Thereafter, the rings were frozen in dry ice-acetone and homogenized in ice-cold 6% trichloroacetic acid.
cGMP was extracted, acetylated and quantified by radioimmunoassay using the Cyclic 
Results
Blood pressure in the thoracic aorta, PRC and PRA after aortic banding.
The increased blood pressure in the thoracic aorta was monitored at the carotid artery following aortic banding. The systolic blood pressure was increased more than 30 mmHg 4 days after aortic banding, and the levels were maintained for 28 days: systolic blood pressures 4, 7, 14 and 28 days after banding were 127.6 ± 4.7, 128.2 ± 3.3, 129.3 ± 1.1, and 153.4 ± 7.8 mmHg, respectively, and were significantly higher than 97.2 ± 2.2, 97.5 ± 4.6, 95.9 ± 3.1, and 97.7 ± 5.9 mmHg in sham-operated rats, respectively, and 96.5 ± 3.1, 97.9 ± 3.7, 98.3 ± 4.5, and 98.1 ±4.6 mmHg in non-operated rats, respectively (n=5-6; p<0.01).
PRC and PRA were significantly increased at 2 and 4 days after aortic banding and returned to the levels of sham-operated animals at 7 days; both levels remained low 14 and 28 days after banding (Fig. 1) .
AT 1 and AT 2 receptor mRNA levels in the thoracic aorta after aortic banding.
To determine whether the pressure-overload alters the vascular expression of AT 1 and AT 2 receptor mRNAs, we examined the mRNA levels of these receptors in the thoracic aorta by RT-PCR. As shown in Fig. 2 the abdominal aorta (Fig. 1) . These observations were confirmed by quantitative real-time PCR: the levels of AT 2 receptor mRNA increased more than 300% after 4, 7, and 14 days compared with those of age-matched untreated rats or sham-operated rats ( Fig. 2 ). High levels of AT 2 receptor mRNA were also observed after 28 days. We examined thoracic aortas from rats 7 days after banding or sham-operation, because high levels of AT2 receptor mRNA were detected in thoracic aortas of banding rats during this period. The contractions evoked by Ang II were significantly decreased in the pressure-loaded rings at higher concentrations of Ang II, such as 3 x 10 -8 and 1 x 10 -7 M, compared to control rings (Fig. 4A) . Blockade of the AT 2 receptor by PD123319 (1 x 10 -6 M) increased the contractile response to Ang II in the pressure-loaded rings ( Fig. 4C ), but not in control rings (Fig. 4B ).
Involvement of the AT
Then we compared the contractile response to Ang II between the ring preparations from rats treated or untreated with losartan for 7 days after aortic banding, because of the observation that the administration of losartan abolished the upregulation of AT 2 receptor mRNA in the thoracic aorta after pressure-overload. Aortic rings were prepared from rats 24 hr after the final administration of losartan at day 6. As shown concentration-response curves were compared between control and pressure-loaded rings after removal of endothelium, decreased response to Ang II in pressure-loaded rings was not observed, and rather the response was augmented significantly in the pressure-loaded rings at lower concentrations of Ang II between 1 x 10 -10 and 1 x 10 -9 M (Fig. 6C) . PD123319 did not influence the response to Ang II in the endothelium-denuded rings of either control or pressure-loaded rings (data not shown).
To determine the involvement of endothelium-derived NO in the decreased response to Ang II in pressure-loaded rings, the ring preparations with intact endothelium were treated with a NO synthase inhibitor L-NAME (1 x 10 -4 M) for 30 min before the cumulative addition of Ang II. As shown in Fig. 7 , L-NAME pretreatment augmented the contractile response of Ang II in both control and pressure-loaded rings ( Fig. 7A and 7B ), and no significant differences were observed in the response to Ang II between these L-NAME-pretreated rings (Fig. 7C ).
Previous studies have suggested a potential role of the bradykinin/NO system in AT 2 receptor-mediated aortic functions in mice (11). Therefore, we examined the effect of the bradykinin B 2 receptor antagonist icatibant on the decreased response to Ang II in the pressure-loaded rings with intact endothelium, and found that the pretreatment with icatibant (1 x 10 -6 M) for 15 min did not influence the contractile response to Ang II in either control or pressure-loaded rings (data not shown). In both control and pressure-loaded rings, acetylcholine (1 x 10 -8 M) exhibited a relaxation response during constriction evoked by 3 x 10 -7 M phenylephrine, whereas no relaxation was observed by bradykinin up to the concentration of 3 x 10 -6 M (data not shown).
This article has not been copyedited and formatted. The final version may differ from this version. Basal cGMP levels were approximately 2 times greater in pressure-loaded rings than in control rings (8.46 ± 1.39 versus 4.83 ± 1.14 pmol/mg protein; n=4, p<0.05 ) (Fig. 7) . Stimulation with Ang II (1 x 10 -7 M) for 5 min did not significantly affect the cGMP levels in either control or pressure-loaded rings. Treatment with L-NAME (1 x 10 -4 M) for 30 min markedly reduced the cGMP levels not only in control rings (p<0.001), but also in pressure-loaded rings (p<0.001). Ang II (1 x 10 -7 M) did not influence the decreased levels of cGMP in L-NAME-pretreated rings.
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Discussion
In the present study, we found upregulation of the AT 2 receptor mRNA, but not of the AT 1 subtype, in the thoracic aorta under pressure-overload. Since either the administration of losartan or candesartan blunted the upregulation of AT 2 receptor mRNA without showing changes in the banding-induced pressure-overload, it seems likely that the mechanical load upregulates the aortic AT 2 receptor through the action of Ang II, probably via activation of AT 1 receptor. Although high levels of PRC and PRA were observed in animals 4 days after banding as a response of kidney to decreased blood pressure distal to the aortic banding, the levels returned to ranges of sham-operated animals after 7 days, suggesting that the pressure elevation at carotid artery seems to be related to the mechanical obstruction. In fact, the administration of AT 1 receptor antagonists did not decrease blood pressure at carotid artery in rats with aortic banding. These observations may be supported by a finding that enalapril did not reduce the carotid arterial pressure in rats with aortic banding (Baker et al., 1990) .
Several lines of evidence have suggested the existence of a link between the effects of transmural pressure and Ang II in blood vessels. Noda et al. (1994) indicated that mechanical stretch and Ang II synergistically stimulated cultured rat aortic smooth muscle cells to induce a marked increase in the expression of parathyroid hormone-related peptide mRNA. Bardy et al. (1996) AT 2 receptor mRNA was upregulated in rat mesenteric arteries following a pressure dose of Ang II infusion for 2 weeks; they suggested the involvement of AT 1 -receptor mediation in this Ang II effect, because AT 1 receptor antagonist inhibited the Ang II-induced upregulation of the AT 2 receptor. In the aortic banding model, the decreased blood pressure distal to the banding stimulates the kidney to release renin, resulting in increased circulating levels of Ang II. However, as shown in this study and by other investigators (Baker et al., 1990; Doggrell and Brown, 1998) , the fact that the elevation of plasma renin is observed only within a few days after aortic banding does not account for the increased levels of the AT 2 receptor mRNA over three weeks.
Therefore, a rapid increase in AT 2 receptor mRNA levels within 4 days seems to depend on a transient elevation of plasma renin, but the sustained increase in AT 2 receptor mRNA may probably be due to locally generated Ang II in the pressure-overloaded aorta.
In ring preparations of rat thoracic aortas that were dissected 7-days after aortic banding, the contractile response to Ang II was significantly decreased in comparison to that in control rings. The response to Ang II in the pressure-loaded rings was increased in the presence of the AT 2 receptor antagonist PD123319, but not in the control rings, suggesting a potential role of the AT 2 receptor in the decreased aortic response to Ang II.
Indeed, the reduction of Ang II-responsiveness in pressure-loaded rings was prevented by the administration of losartan, which was found to inhibit the upregulation of AT 2 receptor mRNA after aortic banding. Since Ang II binds to the AT 1 and AT 2 receptor subtypes with similar affinity (Nouet and Nahmias, 2000) , the contractile response of the aorta to Ang II seems to be dependent on the relative expression level and/or responsiveness of both receptors. Thus it seems likely that the decreased response to Ang II in the pressure-overloaded aortas depends on, at least in part, the upregulation of the AT 2 receptor.
There is evidence that Ang II binding to AT 2 receptors decreases the Gq-coupled phospholipase C activation by the AT 1 receptor (Gyurko et al., 1992) , suggesting that the activation of AT 2 receptors on aortic smooth muscle cells directly interacts with the signaling pathway of AT 1 receptors. However, a decreased response to Ang II was not observed in the endothelium-denuded rings of pressure-overloaded aortas, and PD123319 did not alter the response to Ang II in the pressure-loaded rings, as well as in the control rings, after removal of the endothelium. Thus it appears that the contraction of aortic smooth muscle cells by Ang II via the AT 1 receptor is attenuated by a vasorelaxation factor(s) derived from the endothelium via AT 2 receptor stimulation.
A potential factor is NO, because of the observation that, after the inhibition of NO synthase by L-NAME, the response to Ang II became comparable in both control and pressure-loaded rings.
The basal levels of cGMP in pressure-loaded aortic rings were significantly higher than those in control rings. Since the cGMP levels in pressure-loaded rings were significantly reduced after L-NAME treatment, it is likely that the increased levels of basal cGMP in pressure-loaded rings result from the enhanced production of NO by the endothelium of pressure-loaded aortas. In fact, the protein and mRNA levels of endothelial NO synthase are upregulated in pressure-overloaded thoracic aortas after banding of the abdominal aorta (Bouloumie et al., 1997; Barton et al., 2001) . Thus, the increased levels of basal cGMP in pressure-loaded rings may participate with, at least in part, the attenuation of the AT 1 receptor-mediated contractile response.
Given that the increased expression of AT 2 receptors in pressure-loaded aortas is functionally coupled to the NO-cGMP system, it is logical to expect that the stimulation by Ang II results in the elevation of cGMP levels in pressure-loaded rings, because of observations that the contractile response to Ang II in pressure-loaded rings was significantly increased by PD123319. However, stimulation by Ang II did not affect the cGMP levels in pressure-loaded rings, as in control rings. These results do not support the idea that the decreased response to Ang II observed in pressure-loaded rings simply depends on the NO-cGMP system via the activation of the AT 2 receptor. Thus it is reasonable to consider mechanisms other than the NO-cGMP system to explain the AT 2 receptor-mediated reduction of Ang II-responsiveness in pressure-loaded aortas.
Taken together, the decreased contractile response to Ang II in thoracic aorta by pressure-overload appears to result from at least two different mechanisms: one is the pressure-overload-induced activation of the NO-cGMP system, and another the AT 2 receptor-dependent vasodilatory mechanisms, such as the activation of phospholipase A 2 and release of arachidonic acid (Zhu et al., 1998) .
It has recently been demonstrated that the AT 2 -receptor-mediated vasodilator response to Ang II is mediated by kinin in various vessels, such as the rat aorta (Gohlke et al., 1998) , canine coronary microvessels (Seyedi et al., 1995) to the local generation of kinin in the vascular wall, which stimulates NO production in endothelial cells via the bradykinin B 2 receptor. However, as shown in the present study, the decreased response to Ang II in pressure-loaded rings was not affected by the B 2 receptor antagonist icatibant. Furthermore, both control and pressure-loaded rings did not exhibit a relaxation response to exogenous bradykinin, even at high concentrations, in contrast to the sensitive relaxation by acetylcholine, indicating that the rat thoracic aorta is essentially insensitive to bradykinin. This observation is supported by a previous study (Wirth et al., 1996) that rat aorta shows vasorelaxation in response to acetycholine, but not to bradykinin. Thus it is unlikely that the kinin-NO-cGMP system plays a role in the signaling cascade of the AT 2 -receptor in the rat thoracic aorta.
Recent studies on the vascular AT 2 receptor have focused on the pathophysiological roles under hypertensive conditions in which vascular AT 2 receptors are upregulated, such as in the mesenteric arteries of young spontaneously hypertensive rats (SHR) (Touyz et al., 1999) and in the thoracic aorta of SHR (Otsuka et al., 1998) . Barber et al. (1999) 
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